Strides Pharma Science Ltd has reported a consolidated net loss of Rs 163.4 crore in the first quarter ended in June 2022, compensated by higher revenue. The company reported a consolidated net loss of Rs 244.1 crore for the same quarter a year ago. Revenue from operations stood at Rs 940.07 crore compared to Rs 688.37 crore in the year-ago period, marking a growth of 36.6 per cent.

• Developers Race to Remove Anthropic’s Invisible AI Watermarks
• Godrej Industries Plans Rs 20,000 Crore Investment in Haryana
• Asaya Raises Rs 88 Crore, Plans Offline Retail Expansion
• NTPC Green Energy Arm Wins 500 MW SECI Peak Power Tender
• Natco Pharma Facility Gets 4 USFDA Observations; Shares Up 

The company reported that its revenues from Other Regulated Markets (ORM) were at Rs 304.7 crore in the first quarter of FY23, compared to Rs 223.2 crore in the corresponding fiscal period. Higher costs remain a cause of concern, and the company is focused on cost controls and manufacturing network optimization.